JAKZ (Javna agencija Republike Slovenije za kakovost v zdravstvu) issued the Act on Health Technology Assessment, Akt o vrednotenju zdravstvenih tehnologij (SOP 2026-01-2538), in the Official Gazette of the Republic of Slovenia as UL RS 1878/26 on November 11, 2026 (PDF). Article 21 starts it on the fifteenth day after publication: November 26, 2026.

From November 26, 2026, marketing authorisation holders filing for public reimbursement of medicines in Slovenia, manufacturers and distributors of medical devices and IVDs seeking inclusion in Slovenian publicly funded care, and market-access consultancies that prepare HTA dossiers for the Slovenian payer must file any Slovenian HTA application with a clinical part built on the Slovenian PICO frames or a cited EU joint clinical assessment under Regulation (EU) 2021/2282, and a non-clinical part that reports ICER and QALY at a 3.5 percent discount, an ICER threshold equal to Slovenian GDP per capita, one-way and probabilistic sensitivity analyses of at least 1,000 runs, a scenario analysis and a budget-impact study from the public-payer perspective, or an application that is not completed within the agency's deadline of at most 30 days is not assessed, so the technology is not evaluated for use of compulsory health-insurance or budget funds. Until the Article 3 portal exists, Article 20 sends the published form to [email protected]. Any other route is not examined.

What does UL RS 1878/26 require in the dossier?

From November 26, 2026 the file has a clinical part and a non-clinical part, under Article 3 and Article 34(3) of the Healthcare Quality Assurance Act (Zakon o zagotavljanju kakovosti v zdravstvu, ZZKZ, UL RS 102/24 and 111/25). ICER is the ratio between the incremental cost and the incremental effectiveness of a health technology.

The clinical part drops out when a joint clinical assessment under Regulation (EU) 2021/2282 is cited. Otherwise it follows that regulation's implementing acts and every PICO frame of Slovenian practice. Article 2 defines PICO as population and problem, intervention, comparator and outcomes. Other EU or international data may fill gaps if justified. Article 1(2) keeps the national file separate from the EU joint procedure.

Article 5 requires ICER and QALY, a 3.5 percent discount and an ICER threshold equal to Slovenian GDP per capita, or a reasoned cost-minimisation, cost-utility or cost-benefit analysis, plus a financial-effects study. Each study needs a one-way sensitivity analysis, a probabilistic analysis of at least 1,000 runs, and a scenario analysis. The perspective is compulsory insurance (OZZ) and the state budget.

ElementRuleBasis
RouteJAKZ portal, or [email protected] until it existsArticles 3 and 20
Clinical partSlovenian PICO, or a cited EU joint clinical assessmentArticle 4
ICER settings3.5 percent discount, threshold equal to GDP per capitaArticle 5(1)
UncertaintyOne-way, at least 1,000 probabilistic runs, scenariosArticle 5(2)
CompletenessChecked in 15 days, supplement within at most 30 daysArticle 14

Who must file, and which files JAKZ ranks first?

The proposer is whoever seeks an assessment for financing from Slovenian public funds: the marketing authorisation holder, the device or IVD company, or the consultancy that writes the dossier. Obsidian tracks 5 regulatory texts, in force, amended or in preparation, for the Life Sciences and MedTech industry in Slovenia, as of November 2026.

Article 6 orders the queue with ZZKZ Article 33(3) and does not score those criteria. A file is a priority when the three-year public-spend gap exceeds EUR 1,000,000.

When does the report support inclusion, and when does it refuse it?

The Article 17 report states findings, intended use, both assessments and a funding recommendation. Article 13 scores 100 points: clinical value 35, disease burden 15, economic value 20, and 10 each for societal impact, ethics and equity, and organisational feasibility.

Under Article 19 the points do not themselves decide. As a rule, 55 or more can support inclusion, 40 to 54 inclusion on conditions, and under 40 a refusal or more data. No inclusion if certainty on key outcomes is very low. At most a conditional recommendation if certainty is low, the ICER exceeds the Article 5 threshold, or a cost-benefit ratio is below 1.

What is the consequence of an incomplete file?

Article 14: JAKZ checks completeness within 15 days. The proposer then has at most 30 days to finish the file, and that interval does not count toward the assessment deadline. If the file stays incomplete, JAKZ does not assess it, so the technology is not evaluated for compulsory health-insurance or budget funds. A new assessment opens when new clinical evidence, price, volume or comparators would change the report, or a conditional recommendation expires.

From November 26, 2026, each model in a Slovenian HTA file uses the Article 5 discount, threshold and 1,000-run analysis. Continuous, per-jurisdiction monitoring surfaces a gazette act of this kind the moment it is published.

Live
Slovenia life sciences: Medicinal Products Act transposition of the EU pharmaceutical package, medical device registrati
Monitor national implementation of EU medicines, medical-device and health-technology-assessment rules for medicinal products and devices placed on the Slovenian market.
Email 40+ news

Confirm the product is aimed at Slovenian public funding, lock the non-clinical model to Article 5, and brief market access for filings from November 26, 2026. Obsidian holds the gazette text next to that filing route.